2015
Sex Differences in Varenicline Efficacy for Smoking Cessation: A Meta-Analysis
McKee SA, Smith PH, Kaufman M, Mazure CM, Weinberger AH. Sex Differences in Varenicline Efficacy for Smoking Cessation: A Meta-Analysis. Nicotine & Tobacco Research 2015, 18: 1002-1011. PMID: 26446070, PMCID: PMC5942618, DOI: 10.1093/ntr/ntv207.Peer-Reviewed Original ResearchConceptsSmoking cessation medicationsCessation medicationsSmoking cessationDouble-blind placebo-controlled trialEfficacy of vareniclinePlacebo-controlled trialShort-term outcomesClinical trial dataSex differencesSimilar ratesWeek 52Week 24Women smokersNicotine replacementWeek 12Outcome endpointsTherapeutic responseClinical trialsContinuous abstinenceVarenicline's efficacyVareniclinePlacebo outcomesEqual efficacySex disparitiesEffective FDA
2010
Menstrual cycle phase at quit date and smoking abstinence at 6 weeks in an open label trial of bupropion
Mazure CM, Toll B, McKee SA, Wu R, O’Malley S. Menstrual cycle phase at quit date and smoking abstinence at 6 weeks in an open label trial of bupropion. Drug And Alcohol Dependence 2010, 114: 68-72. PMID: 20832955, PMCID: PMC3016455, DOI: 10.1016/j.drugalcdep.2010.07.024.Peer-Reviewed Original ResearchConceptsMenstrual cycle phaseQuit datePoint prevalence abstinencePremenopausal womenBupropion SRFollicular phaseLuteal phaseAbsence of pharmacotherapySustained release bupropionOpen-label trialCycle phaseMechanism of actionRelease bupropionLabel trialNicotine replacementCessation interventionsOpen trialTreatment completionCessation outcomesContinuous abstinenceQuit dayGonadal hormonesTreatment periodAbstinence outcomesQuit attemptsExploring the impact of gender and reproductive status on outcomes in a randomized clinical trial of naltrexone augmentation of nicotine patch
Epperson CN, Toll B, Wu R, Amin Z, Czarkowski KA, Jatlow P, Mazure CM, O’Malley S. Exploring the impact of gender and reproductive status on outcomes in a randomized clinical trial of naltrexone augmentation of nicotine patch. Drug And Alcohol Dependence 2010, 112: 1-8. PMID: 20561758, PMCID: PMC2946976, DOI: 10.1016/j.drugalcdep.2010.04.021.Peer-Reviewed Original ResearchConceptsPlacebo groupStudy completersNaltrexone doseClinical trialsContinuous abstinenceOral naltrexone treatmentNicotine patch therapyNicotine replacement therapyInteractive voice responseRandomized clinical trialsMenstrual cycle statusEffect of doseNaltrexone augmentationNaltrexone groupAdverse eventsNaltrexone treatmentNicotine patchPatch therapyReplacement therapyQuit dayWeek 1AbstinenceDoseWomenLess adherent